HC Wainwright Issues Positive Estimate for SRPT Earnings

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Equities researchers at HC Wainwright raised their Q1 2025 EPS estimates for shares of Sarepta Therapeutics in a research report issued to clients and investors on Wednesday, January 15th. HC Wainwright analyst M. Kapoor now anticipates that the biotechnology company will post earnings of $2.45 per share for the quarter, up from their previous estimate of $2.35. HC Wainwright currently has a "Sell" rating and a $75.00 target price on the stock. The consensus estimate for Sarepta Therapeutics' current full-year earnings is $2.17 per share. HC Wainwright also issued estimates for Sarepta Therapeutics' Q4 2025 earnings at $2.85 EPS.

SRPT has been the topic of a number of other reports. StockNews.com downgraded Sarepta Therapeutics from a "buy" rating to a "hold" rating in a report on Wednesday, November 20th. Jefferies Financial Group initiated coverage on Sarepta Therapeutics in a research note on Monday, October 21st. They issued a "buy" rating and a $165.00 target price on the stock. Guggenheim increased their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $182.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, October 21st. Finally, Piper Sandler reduced their price objective on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating for the company in a research note on Wednesday, November 27th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $178.71.

Sarepta Therapeutics Stock Down 1.9 %

NASDAQ:SRPT traded down $2.27 during trading hours on Thursday, reaching $117.06. The company's stock had a trading volume of 829,494 shares, compared to its average volume of 802,509. The stock has a 50 day moving average price of $121.75 and a two-hundred day moving average price of $130.06. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The company has a market capitalization of $11.18 billion, a P/E ratio of 93.65 and a beta of 0.77. Sarepta Therapeutics has a 12 month low of $102.15 and a 12 month high of $173.25.

Institutional Trading of Sarepta Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Teachers Retirement System of The State of Kentucky purchased a new stake in Sarepta Therapeutics in the 2nd quarter worth approximately $4,771,000. Simplify Asset Management Inc. lifted its stake in shares of Sarepta Therapeutics by 84.6% in the 3rd quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company's stock valued at $24,105,000 after purchasing an additional 88,474 shares during the period. Geode Capital Management LLC boosted its holdings in Sarepta Therapeutics by 2.7% during the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company's stock worth $211,910,000 after buying an additional 44,306 shares in the last quarter. Summit Partners Public Asset Management LLC grew its position in Sarepta Therapeutics by 547.9% during the third quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company's stock valued at $17,250,000 after buying an additional 116,800 shares during the period. Finally, Larson Financial Group LLC increased its holdings in Sarepta Therapeutics by 1,649.8% in the third quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company's stock valued at $1,093,000 after buying an additional 8,249 shares in the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Sarepta Therapeutics

In related news, Director Kathryn Jean Boor sold 1,636 shares of the firm's stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the transaction, the director now owns 5,880 shares of the company's stock, valued at $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company's stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now directly owns 22,840 shares in the company, valued at approximately $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is owned by insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.